<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03535701</url>
  </required_header>
  <id_info>
    <org_study_id>OSU-16289</org_study_id>
    <secondary_id>NCI-2017-01168</secondary_id>
    <nct_id>NCT03535701</nct_id>
  </id_info>
  <brief_title>Ketogenic Diet and Chemotherapy in Affecting Recurrence in Patients With Stage IV Breast Cancer</brief_title>
  <acronym>KETO-CARE</acronym>
  <official_title>Ketogenic Diet and Chemotherapy to Affect Recurrence of Breast Cancer (The KETO-CARE Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ohio State University Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot clinical trial studies how well a ketogenic diet and chemotherapy work in&#xD;
      affecting the return of cancer in patients with stage IV breast cancer. Ketogenic diet may be&#xD;
      more effective than standard nutrition and may affect quality of life, inflammation, and&#xD;
      tumor-related changes. Drugs used in chemotherapy, such as paclitaxel, work in different ways&#xD;
      to stop the growth of tumor cells, either by killing the cells, by stopping them from&#xD;
      dividing, or by stopping them from spreading. Giving ketogenic diet and chemotherapy may be&#xD;
      better in patients with breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate the feasibility of implementing a diet that induces nutritional ketosis in&#xD;
      women who are initiating palliative chemotherapy to treat advanced stage breast cancer (BC).&#xD;
&#xD;
      II. To determine the effects of a ketogenic diet on tumor progression. III. To determine the&#xD;
      effects of nutritional ketosis on biologic and behavioral health markers.&#xD;
&#xD;
      OUTLINE: Patients are assigned to 1 of 2 arms.&#xD;
&#xD;
      ARM I: Patients receive standard of care therapy with paclitaxel.&#xD;
&#xD;
      ARM II: Patients receive standard of care with paclitaxel. Patients undergo a controlled&#xD;
      feeding period ketogenic diet comprising of meals prepared in the research kitchen for 3&#xD;
      months. Beginning 2 weeks prior to completion of the controlled feeding period, patients also&#xD;
      undergo free living ketogenic diet program for 3 months comprising of group format,&#xD;
      individual sessions, and online digital content to educate patients to implement a ketogenic&#xD;
      eating pattern into their lifestyle.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 20, 2017</start_date>
  <completion_date type="Actual">May 1, 2020</completion_date>
  <primary_completion_date type="Actual">March 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adherence and compliance to the ketogenic diet</measure>
    <time_frame>Up to 26 weeks</time_frame>
    <description>Summaries from diet assessments and ketone logs will be plotted over time to assess adherence and compliance to the ketogenic diet.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in psychosocial measures</measure>
    <time_frame>Baseline up to 26 weeks</time_frame>
    <description>Summary measures such as Cohens d will be used. Linear and nonlinear mixed models will be used as appropriate to model changes in tumor markers, comorbidity risk factors, and other measures over time, with emphasis will be on estimating effect sizes (such as slopes of change). Post hoc tests will be used to examine pairwise comparisons when significant main or interaction effects are observed. The alpha level for significance will be set at p =&lt; 0.05.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in physiologic outcomes</measure>
    <time_frame>Baseline up to 26 weeks</time_frame>
    <description>Summary measures such as Cohens d will be used. Linear and nonlinear mixed models will be used as appropriate to model changes in tumor markers, comorbidity risk factors, and other measures over time, with emphasis will be on estimating effect sizes (such as slopes of change). Post hoc tests will be used to examine pairwise comparisons when significant main or interaction effects are observed. The alpha level for significance will be set at p =&lt; 0.05.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Stage IV Breast Cancer AJCC v6 and v7</condition>
  <arm_group>
    <arm_group_label>Arm I (standard of care)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive standard of care therapy with paclitaxel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (standard of care, ketogenic diet)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive standard of care with paclitaxel. Patients undergo a controlled feeding period ketogenic diet comprising of meals prepared in the research kitchen for 3 months. Beginning 2 weeks prior to completion of the controlled feeding period, patients also undergo free living ketogenic diet program for 3 months comprising of group format, individual sessions, and online digital content to educate patients to implement a ketogenic eating pattern into their lifestyle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dietary Intervention</intervention_name>
    <description>Undergo ketogenic diet</description>
    <arm_group_label>Arm II (standard of care, ketogenic diet)</arm_group_label>
    <other_name>Dietary Modification</other_name>
    <other_name>intervention, dietary</other_name>
    <other_name>Nutrition Intervention</other_name>
    <other_name>Nutrition Interventions</other_name>
    <other_name>Nutritional Interventions</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (standard of care)</arm_group_label>
    <arm_group_label>Arm II (standard of care, ketogenic diet)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Given standard of care therapy with paclitaxel</description>
    <arm_group_label>Arm I (standard of care)</arm_group_label>
    <arm_group_label>Arm II (standard of care, ketogenic diet)</arm_group_label>
    <other_name>Anzatax</other_name>
    <other_name>Asotax</other_name>
    <other_name>Bristaxol</other_name>
    <other_name>Praxel</other_name>
    <other_name>Taxol</other_name>
    <other_name>Taxol Konzentrat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (standard of care)</arm_group_label>
    <arm_group_label>Arm II (standard of care, ketogenic diet)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (standard of care)</arm_group_label>
    <arm_group_label>Arm II (standard of care, ketogenic diet)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index (BMI) &gt;= 22 kg/m^2&#xD;
&#xD;
          -  Confirmed diagnosis of metastatic or stage IV BC&#xD;
&#xD;
          -  Fludeoxyglucose F-18 (FDG)-positron emission tomography (PET) avid tumors&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 (0=participant has&#xD;
             either normal activity, 1= participant has some symptoms but is nearly full&#xD;
             ambulatory)&#xD;
&#xD;
          -  Life expectancy &gt; 6 months&#xD;
&#xD;
          -  Able and willing to follow prescribed diet intervention&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior chemotherapy for metastatic breast cancer (MBC) (prior adjuvant chemotherapy&#xD;
             permitted as long as &gt; 12 months [mo])&#xD;
&#xD;
          -  BMI &lt; 25 kg/m^2&#xD;
&#xD;
          -  Weight change &gt; 5% within 3 months of enrollment&#xD;
&#xD;
          -  Type 1 diabetes&#xD;
&#xD;
          -  History of diabetes with retinopathy requiring treatment&#xD;
&#xD;
          -  Current use of insulin or sulfonylureads for glycemic control, or history of&#xD;
             ketoacidosis&#xD;
&#xD;
          -  Intestinal obstruction&#xD;
&#xD;
          -  Bilirubin &gt; 2&#xD;
&#xD;
          -  Albumin &lt; 3.5&#xD;
&#xD;
          -  Glomerular filtration rate (GFR) &lt; 55 mL/min&#xD;
&#xD;
          -  Creatinine &gt; 2.0&#xD;
&#xD;
          -  Urinary albumin &gt; 1 g/day&#xD;
&#xD;
          -  Congestive heart failure&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
&#xD;
          -  Unable to provide informed consent&#xD;
&#xD;
          -  Uncontrolled concurrent medical conditions that would limit compliance with study&#xD;
             requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeff Volek, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer.osu.edu</url>
    <description>The Jamesline</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 9, 2018</study_first_submitted>
  <study_first_submitted_qc>May 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2018</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University Comprehensive Cancer Center</investigator_affiliation>
    <investigator_full_name>Jeff Volek</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

